Two Sigma Investments, LP Prothena Corp Public LTD CO Transaction History

Two Sigma Investments, LP

  • $41.6 Billion
  • Q4 2024

A detailed history of Two Sigma Investments, LP transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Two Sigma Investments, LP holds 38,394 shares of PRTA stock, worth $607,009. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,394
Previous 10,507 265.41%
Holding current value
$607,009
Previous $175,000 203.43%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$11.95 - $18.35 $333,249 - $511,726
27,887 Added 265.41%
38,394 $531,000
Q3 2024

Nov 14, 2024
SELL
$16.73 - $24.79 $1.02 Million - $1.51 Million
-61,052 Reduced 85.32%
10,507 $175,000
Q2 2024

Aug 14, 2024
BUY
$19.54 - $26.15 $1.4 Million - $1.87 Million
71,559 New
71,559 $1.48 Million
Q3 2023

Nov 14, 2023
SELL
$47.3 - $70.6 $1.25 Million - $1.87 Million
-26,530 Reduced 16.3%
136,203 $6.57 Million
Q2 2023

Aug 14, 2023
SELL
$48.26 - $78.59 $9.79 Million - $15.9 Million
-202,806 Reduced 55.48%
162,733 $11.1 Million
Q1 2023

May 15, 2023
BUY
$46.97 - $58.27 $7.61 Million - $9.45 Million
162,104 Added 79.68%
365,539 $17.7 Million
Q4 2022

Feb 14, 2023
BUY
$52.05 - $65.0 $3.53 Million - $4.4 Million
67,750 Added 49.93%
203,435 $12.3 Million
Q3 2022

Nov 14, 2022
SELL
$25.16 - $60.63 $2.38 Million - $5.74 Million
-94,742 Reduced 41.12%
135,685 $8.23 Million
Q2 2022

Aug 15, 2022
SELL
$22.73 - $39.98 $701,538 - $1.23 Million
-30,864 Reduced 11.81%
230,427 $6.26 Million
Q1 2022

May 16, 2022
SELL
$30.27 - $49.22 $1.22 Million - $1.98 Million
-40,163 Reduced 13.32%
261,291 $9.56 Million
Q4 2021

Feb 14, 2022
SELL
$42.11 - $73.26 $830,072 - $1.44 Million
-19,712 Reduced 6.14%
301,454 $14.9 Million
Q3 2021

Nov 15, 2021
SELL
$48.2 - $78.89 $762,716 - $1.25 Million
-15,824 Reduced 4.7%
321,166 $22.9 Million
Q2 2021

Aug 16, 2021
BUY
$21.63 - $57.65 $878,437 - $2.34 Million
40,612 Added 13.7%
336,990 $17.3 Million
Q1 2021

May 17, 2021
BUY
$11.0 - $28.24 $2.7 Million - $6.94 Million
245,797 Added 485.95%
296,378 $7.45 Million
Q4 2020

Feb 16, 2021
SELL
$10.12 - $13.94 $498,207 - $686,266
-49,230 Reduced 49.32%
50,581 $607,000
Q3 2020

Nov 16, 2020
SELL
$9.93 - $13.47 $144,114 - $195,490
-14,513 Reduced 12.69%
99,811 $997,000
Q2 2020

Aug 14, 2020
BUY
$9.56 - $12.51 $305,862 - $400,244
31,994 Added 38.86%
114,324 $1.2 Million
Q1 2020

May 15, 2020
SELL
$7.54 - $15.77 $488,079 - $1.02 Million
-64,732 Reduced 44.02%
82,330 $881,000
Q4 2019

Feb 14, 2020
BUY
$7.48 - $17.01 $194,622 - $442,583
26,019 Added 21.5%
147,062 $2.33 Million
Q3 2019

Nov 14, 2019
SELL
$6.89 - $10.45 $1.7 Million - $2.58 Million
-246,480 Reduced 67.07%
121,043 $949,000
Q2 2019

Aug 14, 2019
SELL
$8.85 - $12.49 $302,678 - $427,170
-34,201 Reduced 8.51%
367,523 $3.89 Million
Q1 2019

May 15, 2019
BUY
$10.32 - $14.49 $393,687 - $552,764
38,148 Added 10.49%
401,724 $4.87 Million
Q4 2018

Feb 14, 2019
BUY
$8.73 - $13.74 $673,685 - $1.06 Million
77,169 Added 26.94%
363,576 $3.75 Million
Q3 2018

Nov 14, 2018
BUY
$12.7 - $15.79 $3.64 Million - $4.52 Million
286,407 New
286,407 $3.75 Million
Q2 2018

Aug 14, 2018
BUY
$10.99 - $44.21 $1.94 Million - $7.79 Million
176,261 New
176,261 $2.57 Million
Q1 2018

May 15, 2018
SELL
$27.95 - $45.04 $352,002 - $567,233
-12,594 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$35.44 - $63.76 $446,331 - $802,993
12,594
12,594 $472,000

Others Institutions Holding PRTA

# of Institutions
198
Shares Held
44.5M
Call Options Held
601K
Put Options Held
259K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $742M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email